Syneos Health price target raised to $51 from $42 at Baird

Baird raised the firm’s price target on Syneos Health to $51 from $42 and keeps an Outperform rating on the shares. The analyst noted the shares rose despite weak Clinical bookings and notable 2023 revenue and profit decline forecast. The Street prepped for disaster; bad results were good enough and with the decks cleared, it is now up to a business development recovery.